Previous Article | Next Article 
Antimicrobial Agents and Chemotherapy, May 2002, p. 1325-1328, Vol. 46, No. 5
0066-4804/02/$04.00+0 DOI: 10.1128/AAC.46.5.1325-1328.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.
Change in Colony Morphology of Candida lusitaniae in Association with Development of Amphotericin B Resistance
Nancy B. McClenny,1* Haihua Fei,2,
Ellen J. Baron,1 Ana C. Gales,3 Allison Houston,3 Richard J. Hollis,3 and Michael A. Pfaller3
Clinical Microbiology/Virology Laboratory,1
Department of Pathology,2
Stanford University Medical Center, Stanford, California 94305, and University of Iowa College of Medicine, Iowa City, Iowa 522423
Received 8 June 2001/
Returned for modification 14 August 2001/
Accepted 5 October 2001
It is not uncommon to see amphotericin B treatment failure in patients with systemic infection caused by Candida lusitaniae. We report a patient with stage IV ovarian carcinoma and C. lusitaniae sepsis whose treatment with amphotericin B failed. The initial blood isolate was susceptible to amphotericin B in vitro; however, the MIC for a blood isolate recovered 7 weeks after treatment began showed a fourfold increase. Direct subculture of two positive blood samples obtained within a week of the patient's death showed the coexistence of two distinct colony color variants on CHROMagar Candida (CAC). One variant was susceptible to amphotericin B, and one was resistant. These results emphasize the importance of repeat amphotericin B susceptibility testing for patients with persistent C. lusitaniae infection. The presence of colony variants on CAC may signal the emergence of amphotericin B resistance in C. lusitaniae and should be investigated.
* Corresponding author. Mailing address: Clinical Microbiology Laboratory, Stanford University Medical Center, 300 Pasteur Dr., Stanford, CA 94305-5250. Phone: (650) 723-6671. Fax: (650) 725-5671. E-mail:
nancy.mcclenny{at}medcenter.stanford.edu.
Present address: Quest Diagnostics, Portland, Oreg.
Antimicrobial Agents and Chemotherapy, May 2002, p. 1325-1328, Vol. 46, No. 5
0066-4804/02/$04.00+0 DOI: 10.1128/AAC.46.5.1325-1328.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.
This article has been cited by other articles:
-
Diekema, D. J., Messer, S. A., Boyken, L. B., Hollis, R. J., Kroeger, J., Tendolkar, S., Pfaller, M. A.
(2009). In Vitro Activity of Seven Systemically Active Antifungal Agents against a Large Global Collection of Rare Candida Species as Determined by CLSI Broth Microdilution Methods. J. Clin. Microbiol.
47: 3170-3177
[Abstract]
[Full Text]
-
Pfaller, M. A., Diekema, D. J.
(2007). Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem. Clin. Microbiol. Rev.
20: 133-163
[Abstract]
[Full Text]
-
Miller, N. S., Dick, J. D., Merz, W. G.
(2006). Phenotypic Switching in Candida lusitaniae on Copper Sulfate Indicator Agar: Association with Amphotericin B Resistance and Filamentation. J. Clin. Microbiol.
44: 1536-1539
[Abstract]
[Full Text]
-
D'Souza, H. A., Campbell, M., Baron, E. J.
(2004). Practical Bench Comparison of BBL CHROMagar Orientation and Standard Two-Plate Media for Urine Cultures. J. Clin. Microbiol.
42: 60-64
[Abstract]
[Full Text]
-
Ostrosky-Zeichner, L., Rex, J. H., Pappas, P. G., Hamill, R. J., Larsen, R. A., Horowitz, H. W., Powderly, W. G., Hyslop, N., Kauffman, C. A., Cleary, J., Mangino, J. E., Lee, J.
(2003). Antifungal Susceptibility Survey of 2,000 Bloodstream Candida Isolates in the United States. Antimicrob. Agents Chemother.
47: 3149-3154
[Abstract]
[Full Text]
-
Young, L. Y., Hull, C. M., Heitman, J.
(2003). Disruption of Ergosterol Biosynthesis Confers Resistance to Amphotericin B in Candida lusitaniae. Antimicrob. Agents Chemother.
47: 2717-2724
[Abstract]
[Full Text]